Soft tissue sarcoma, version 2.2012 featured updates to the NCCN guidelines

Margaret Von Mehren; Robert S. Benjamin; Marilyn M. Bui; Ephraim S. Casper; Ernest U. Conrad; Thomas F. DeLaney; Kristen N. Ganjoo; Suzanne George; Ricardo Gonzalez; Martin J. Heslin; John M. Kane; Joel Mayerson; Sean V. McGarry; Christian Meyer; Richard J. O'Donnell; I. Benjamin Paz; John D. Pfeifer; Raphael E. Pollock; R. Lor Randall; Richard F. Riedel; Scott Schuetze; Karen D. Schupak; Herbert S. Schwartz; Sridhar Shankar; Brian A. Van Tine; Jeffrey Wayne; Hema Sundar; Nicole R. McMillian

doi:10.6004/jnccn.2012.0099

Soft tissue sarcoma, version 2.2012 featured updates to the NCCN guidelines

Margaret Von Mehren, Robert S. Benjamin, Marilyn M. Bui, Ephraim S. Casper, Ernest U. Conrad, Thomas F. DeLaney, Kristen N. Ganjoo, Suzanne George, Ricardo Gonzalez, Martin J. Heslin, John M. Kane, Joel Mayerson, Sean V. McGarry, Christian Meyer, Richard J. O'Donnell, I. Benjamin Paz, John D. Pfeifer, Raphael E. Pollock, R. Lor Randall, Richard F. RiedelScott Schuetze, Karen D. Schupak, Herbert S. Schwartz, Sridhar Shankar, Brian A. Van Tine, Jeffrey Wayne, Hema Sundar, Nicole R. McMillian

Research output: Contribution to journal › Review article › peer-review

113 Scopus citations

Abstract

The major changes to the 2012 and 2011 NCCN Guidelines for Soft Tissue Sarcoma pertain to the management of patients with gastrointestinal stromal tumors (GISTs) and desmoid tumors (aggressive fibromatosis). Postoperative imatinib following complete resection for primary GIST with no preoperative imatinib is now included as a category 1 recommendation for patients with intermediate or high risk of recurrence. The panel also reaffirmed the recommendation for preoperative use of imatinib in patients with GISTs that are resectable with negative margins but associated with significant surgical morbidity. Observation was included as an option for patients with resectable desmoid tumors that are small and asymptomatic, not causing morbidity, pain, or functional limitation. Sorafenib is included as an option for systemic therapy for patients with desmoid tumors.

Original language	English (US)
Pages (from-to)	951-960
Number of pages	10
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	10
Issue number	8
DOIs	https://doi.org/10.6004/jnccn.2012.0099
State	Published - Aug 1 2012

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2012.0099

Cite this

Von Mehren, M., Benjamin, R. S., Bui, M. M., Casper, E. S., Conrad, E. U., DeLaney, T. F., Ganjoo, K. N., George, S., Gonzalez, R., Heslin, M. J., Kane, J. M., Mayerson, J., McGarry, S. V., Meyer, C., O'Donnell, R. J., Paz, I. B., Pfeifer, J. D., Pollock, R. E., Randall, R. L., ... McMillian, N. R. (2012). Soft tissue sarcoma, version 2.2012 featured updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 10(8), 951-960. https://doi.org/10.6004/jnccn.2012.0099

Von Mehren, M, Benjamin, RS, Bui, MM, Casper, ES, Conrad, EU, DeLaney, TF, Ganjoo, KN, George, S, Gonzalez, R, Heslin, MJ, Kane, JM, Mayerson, J, McGarry, SV, Meyer, C, O'Donnell, RJ, Paz, IB, Pfeifer, JD, Pollock, RE, Randall, RL, Riedel, RF, Schuetze, S, Schupak, KD, Schwartz, HS, Shankar, S, Van Tine, BA, Wayne, J, Sundar, H & McMillian, NR 2012, 'Soft tissue sarcoma, version 2.2012 featured updates to the NCCN guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 10, no. 8, pp. 951-960. https://doi.org/10.6004/jnccn.2012.0099

@article{5e3a9977d9fb41f1a6ee6f9bde59899f,

title = "Soft tissue sarcoma, version 2.2012 featured updates to the NCCN guidelines",

abstract = "The major changes to the 2012 and 2011 NCCN Guidelines for Soft Tissue Sarcoma pertain to the management of patients with gastrointestinal stromal tumors (GISTs) and desmoid tumors (aggressive fibromatosis). Postoperative imatinib following complete resection for primary GIST with no preoperative imatinib is now included as a category 1 recommendation for patients with intermediate or high risk of recurrence. The panel also reaffirmed the recommendation for preoperative use of imatinib in patients with GISTs that are resectable with negative margins but associated with significant surgical morbidity. Observation was included as an option for patients with resectable desmoid tumors that are small and asymptomatic, not causing morbidity, pain, or functional limitation. Sorafenib is included as an option for systemic therapy for patients with desmoid tumors.",

author = "{Von Mehren}, Margaret and Benjamin, {Robert S.} and Bui, {Marilyn M.} and Casper, {Ephraim S.} and Conrad, {Ernest U.} and DeLaney, {Thomas F.} and Ganjoo, {Kristen N.} and Suzanne George and Ricardo Gonzalez and Heslin, {Martin J.} and Kane, {John M.} and Joel Mayerson and McGarry, {Sean V.} and Christian Meyer and O'Donnell, {Richard J.} and Paz, {I. Benjamin} and Pfeifer, {John D.} and Pollock, {Raphael E.} and Randall, {R. Lor} and Riedel, {Richard F.} and Scott Schuetze and Schupak, {Karen D.} and Schwartz, {Herbert S.} and Sridhar Shankar and {Van Tine}, {Brian A.} and Jeffrey Wayne and Hema Sundar and McMillian, {Nicole R.}",

note = "Funding Information: This work is financially supported by the European project TECHNEAU and Agence de l{\textquoteright}eau Seine— Normandie (AESN). Long and useful discussions we had with Pascal Roche, David Benanou and Karine Drouet are greatly appreciated.",

year = "2012",

month = aug,

day = "1",

doi = "10.6004/jnccn.2012.0099",

language = "English (US)",

volume = "10",

pages = "951--960",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "8",

}

TY - JOUR

T1 - Soft tissue sarcoma, version 2.2012 featured updates to the NCCN guidelines

AU - Von Mehren, Margaret

AU - Benjamin, Robert S.

AU - Bui, Marilyn M.

AU - Casper, Ephraim S.

AU - Conrad, Ernest U.

AU - DeLaney, Thomas F.

AU - Ganjoo, Kristen N.

AU - George, Suzanne

AU - Gonzalez, Ricardo

AU - Heslin, Martin J.

AU - Kane, John M.

AU - Mayerson, Joel

AU - McGarry, Sean V.

AU - Meyer, Christian

AU - O'Donnell, Richard J.

AU - Paz, I. Benjamin

AU - Pfeifer, John D.

AU - Pollock, Raphael E.

AU - Randall, R. Lor

AU - Riedel, Richard F.

AU - Schuetze, Scott

AU - Schupak, Karen D.

AU - Schwartz, Herbert S.

AU - Shankar, Sridhar

AU - Van Tine, Brian A.

AU - Wayne, Jeffrey

AU - Sundar, Hema

AU - McMillian, Nicole R.

N1 - Funding Information: This work is financially supported by the European project TECHNEAU and Agence de l’eau Seine— Normandie (AESN). Long and useful discussions we had with Pascal Roche, David Benanou and Karine Drouet are greatly appreciated.

PY - 2012/8/1

Y1 - 2012/8/1

N2 - The major changes to the 2012 and 2011 NCCN Guidelines for Soft Tissue Sarcoma pertain to the management of patients with gastrointestinal stromal tumors (GISTs) and desmoid tumors (aggressive fibromatosis). Postoperative imatinib following complete resection for primary GIST with no preoperative imatinib is now included as a category 1 recommendation for patients with intermediate or high risk of recurrence. The panel also reaffirmed the recommendation for preoperative use of imatinib in patients with GISTs that are resectable with negative margins but associated with significant surgical morbidity. Observation was included as an option for patients with resectable desmoid tumors that are small and asymptomatic, not causing morbidity, pain, or functional limitation. Sorafenib is included as an option for systemic therapy for patients with desmoid tumors.

AB - The major changes to the 2012 and 2011 NCCN Guidelines for Soft Tissue Sarcoma pertain to the management of patients with gastrointestinal stromal tumors (GISTs) and desmoid tumors (aggressive fibromatosis). Postoperative imatinib following complete resection for primary GIST with no preoperative imatinib is now included as a category 1 recommendation for patients with intermediate or high risk of recurrence. The panel also reaffirmed the recommendation for preoperative use of imatinib in patients with GISTs that are resectable with negative margins but associated with significant surgical morbidity. Observation was included as an option for patients with resectable desmoid tumors that are small and asymptomatic, not causing morbidity, pain, or functional limitation. Sorafenib is included as an option for systemic therapy for patients with desmoid tumors.

UR - http://www.scopus.com/inward/record.url?scp=84865312235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865312235&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2012.0099

DO - 10.6004/jnccn.2012.0099

M3 - Review article

C2 - 22878820

AN - SCOPUS:84865312235

SN - 1540-1405

VL - 10

SP - 951

EP - 960

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 8

ER -

Soft tissue sarcoma, version 2.2012 featured updates to the NCCN guidelines

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this